The use of non-steroidal anti-inflammatory drugs (
NSAIDs) for the treatment of inflammatory
pain is limited by gastrointestinal complications. The rapid action of
NSAIDs is associated with better
pain relief. Previously, we demonstrated that
fluoro-loxoprofen, a novel
NSAID, has less ulcerogenic potential than other
NSAIDs, attributable to its gastroprotective properties. The aim of this study was to investigate and compare the effects of
fluoro-loxoprofen on inflammatory
pain in rats with those of other
NSAIDs.
Oral administration of
fluoro-loxoprofen,
loxoprofen, and
celecoxib resulted in equivalent
analgesic action against yeast-induced inflammatory
pain. The antinociceptive effect of
fluoro-loxoprofen was maximized within 1 h after administration, which is less time than that observed for
loxoprofen (2 h) and
celecoxib (3 h). We confirmed that both
fluoro-loxoprofen and
loxoprofen suppressed the increases in
prostaglandin E2 in inflamed paws. In addition to yeast-induced
pain,
fluoro-loxoprofen produced a similar effect against adjuvant-induced inflammatory
pain, with faster peak
analgesic effects than those observed for
loxoprofen and
celecoxib. Taken together, these results suggest that the
analgesic effect of
fluoro-loxoprofen is equivalent to that of
loxoprofen and
celecoxib. Moreover, the
analgesic effect of
fluoro-loxoprofen against inflammatory
pain was more rapid than that of other
NSAIDs, and this may be associated with its rapid absorption property.